earnings

Medtronic rises on Street-beating Q2 driven by ventilator sales
Medtronic rises on Street-beating Q2 driven by ventilator sales
Mass Device
Medtronic
earnings
devices
COVID-19
ventilators
Flag link:
No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program
No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program
Motley Fool
BioNTech
earnings
vaccines
COVID-19
Flag link:
Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal
Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal
Motley Fool
Novavax
vaccines
earnings
COVID-19
Flag link:
Why Emergent BioSolutions Slipped on Friday
Why Emergent BioSolutions Slipped on Friday
Motley Fool
Emergent BioSolutions
earnings
Flag link:
How BioMarin Beat Expectations in Q3
How BioMarin Beat Expectations in Q3
Motley Fool
Biomarin
hemophilia A
earnings
Flag link:
How Bristol Myers Squibb Beat Wall Street Estimates in Q3
How Bristol Myers Squibb Beat Wall Street Estimates in Q3
Motley Fool
Bristol-Myers Squibb
earnings
Flag link:
AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track
AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track
Pharmaforum
AstraZeneca
earnings
vaccines
COVID-19
Flag link:
Regeneron Posts Better-Than-Expected Third-Quarter Earnings
Regeneron Posts Better-Than-Expected Third-Quarter Earnings
TheStreet.com
Regeneron
earnings
COVID-19
Flag link:
Lundbeck tops Q3 expectations following strong sales of mental health drugs
Lundbeck tops Q3 expectations following strong sales of mental health drugs
Pharmaforum
Lundbeck
earnings
Flag link:
How AbbVie Beat Expectations in Q3
How AbbVie Beat Expectations in Q3
Motley Fool
AbbVie
earnings
Humira
Flag link:
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Endpoints
Novo Nordisk
earnings
NASH
semaglutide
breakthrough therapy
FDA
Flag link:
In early blow to Kenji Yasukawa's R&D revamp, Astellas drops out of the TIGIT race without explanation
In early blow to Kenji Yasukawa's R&D revamp, Astellas drops out of the TIGIT race without explanation
Endpoints
Astellas
earnings
anti-TIGIT
R&D
Flag link:
Why Illumina's Q3 Results Were Better Than They Might Seem
Why Illumina's Q3 Results Were Better Than They Might Seem
Motley Fool
Illumina
diagnostics
earnings
Flag link:
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates
Yahoo/Zacks.com
Vertex Pharmaceuticals
earnings
Flag link:
Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp
Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp
Fierce Pharma
Sanofi
earnings
Dupixent
Paul Hudson
Pharma CEOs
Flag link:
Thank Otezla for Amgen's Q3 Revenue and Earnings Beats
Thank Otezla for Amgen's Q3 Revenue and Earnings Beats
Motley Fool
Amgen
earnings
Otezla
Flag link:
Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
Motley Fool
Gilead Sciences
earnings
Veklury
remdesivir
COVID-19
Flag link:
Merck raises annual profit outlook as Keytruda drives profit beat
Merck raises annual profit outlook as Keytruda drives profit beat
CNBC
Merck
earnings
Keytruda
Flag link:
2 Fumbles and 1 Gift in Biogen's Latest Earnings Report
2 Fumbles and 1 Gift in Biogen's Latest Earnings Report
Motley Fool
Biogen
earnings
Spinraza
Flag link:
How Pfizer Missed an Opportunity With Its Q3 Results
How Pfizer Missed an Opportunity With Its Q3 Results
Motley Fool
Pfizer
earnings
Flag link:

Pages